The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic

Hans H Liu, Michael D Ezekowitz, Michele Columbo, Oneib Khan, Jack Martin, Judith Spahr, David Yaron, Lisa Cushinotto, Luciano Kapelusznik, Hans H Liu, Michael D Ezekowitz, Michele Columbo, Oneib Khan, Jack Martin, Judith Spahr, David Yaron, Lisa Cushinotto, Luciano Kapelusznik

Abstract

Background: The World Health Organization declared the outbreak of SARS-CoV-2 a pandemic on February 11, 2020. This organism causes COVID-19 disease and the rapid rise in cases and geographic spread strained healthcare systems. Clinical research trials were hindered by infection control measures discouraging physical contact and diversion of resources to meet emergent requirements. The need for effective treatment and prevention of COVID-19 prompted an untested investigational response. Trial groups adapted approaches using remote enrolment and consenting, newly developed diagnostic tests, delivery of study medications and devices to participants' homes, and remote monitoring to ensure investigator/enrollee safety while preserving ethical integrity, confidentiality, and data accuracy.

Methods: Clinical researchers at our community health system in the USA undertook an outpatient randomized open-label study of hydroxychloroquine (HCQ) prophylaxis versus observation of SARS-CoV-2 infection in household COVID-19 contacts. Designed in March 2020, challenges included COVID-19 infection in the research group, HCQ shortage, and lack of well-established home SARS-CoV-2 tests and remote ECG monitoring protocols in populations naive to these procedures. The study was written, funded, and received ethical committee approval in 4 months and was completed by September 2020 during a period of fluctuating infection rates and conflicting political opinions on HCQ use; results have been published. Singular methodology included the use of a new RNA PCR saliva SARS-CoV-2 home diagnostic test and a remote smartphone-based 6-lead ECG recording system.

Results: Of 483 households contacted regarding trial participation, 209 (43.3%) did not respond to telephone calls/e-mails and 90 (18.6%) declined; others were not eligible by inclusion or exclusion criteria. Ultimately, 54 individuals were enrolled and 42 completed the study. Numbers were too small to determine the efficacy of HCQ prophylaxis. No serious treatment-related adverse events were encountered.

Conclusions: Flexibility in design, a multidisciplinary research team, prompt cooperation among research, funding, ethics review groups, and finding innovative study approaches enabled this work. Concerns were balancing study recruitment against unduly influencing individuals anxious for protection from the pandemic and exclusion of groups based on lack of Internet access and technology. An issue to address going forward is establishing research cooperation across community health systems before emergencies develop.

Trial registration: ClinicalTrials.gov NCT04652648 . Registered on December 3, 2020.

Keywords: COVID-19 pandemic; Hydroxychloroquine; Prospective clinical trial; Remote ECG monitoring; SARS-CoV-2; Trial management.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Number and adequacy of ECGs submitted by study participants. Columns depict tracings per individual listed by date of first ECG; the great majority of ECGs submitted were technically adequate (dark portion of bar) though QTc values could not always be determined (clear portion of bar)

References

    1. Liu HH, Ezekowitz MD, Columbo M, Khan O, Martin J, Spahr J, et al. Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. J Interv Card Electrophysiol. 2021;26:1–12. doi: 10.1007/s10840-021-00989-x.
    1. World Health Organization, [accessed 31 Mar 2021].
    1. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–1567. doi: 10.1056/NEJMc2004973.
    1. Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(12):e2031756. doi: 10.1001/jamanetworkopen.2020.31756.
    1. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577–582. doi: 10.7326/M20-0504.
    1. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T, Gao W, Cheng C, Tang X, Wu X, Wu Y, Sun B, Huang S, Sun Y, Zhang J, Ma T, Lessler J, Feng T. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(8):911–919. doi: 10.1016/S1473-3099(20)30287-5.
    1. Shah K, Saxena D, Mavalankar D. Secondary attack rate of COVID-19 in household contacts: a systematic review. QJM. 2020;113(12):841–850. doi: 10.1093/qjmed/hcaa232.
    1. Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in households — Tennessee and Wisconsin, April–September 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1631–1634. doi: 10.15585/mmwr.mm6944e1.
    1. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. Br Med J. 2020;369:m1375. doi: 10.1136/bmj.m1375.
    1. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30(4):297–308. doi: 10.1016/j.ijantimicag.2007.05.015.
    1. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020;8(5):e639–e640. doi: 10.1016/S2214-109X(20)30114-5.
    1. Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020;20:1118. doi: 10.1016/S1473.3099(20)30296-6.
    1. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-0.
    1. United States Food and Drug Administration: News release “Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease.” March 28, 2020. .
    1. National Task Force for Covid 19. Advisory on the use of hydroxychloroquine as prophylaxis for SARS-CoV-2 infection. New Delhi: ICMR; 2020 March 22 [cited 2020 Apr 14]. Available from: .
    1. Main Line Health System daily admissions, COVID-19 Communications@mlhs.org [accessed 1 Aug 2021].
    1. Pennsylvania 14-day average of COVID-19 cases, [accessed 1 Aug 2021].
    1. United States 7-day average of COVID-19 cases, [accessed 1 Aug 2021].
    1. Sanofi-Aventis Canada Inc., Product Monograph Plaquenil® (Hydroxychloroquine Sulfate Tablets USP 200mg), August 26, 2019. .
    1. Mitchell EJ, Ahmed K, Breeman S, Cotton S, Constable L, Ferry G, Goodman K, Hickey H, Meakin G, Mironov K, Quann N, Wakefield N, McDonald A. It is unprecedented: trial management during the COVID-19 pandemic and beyond. Trials. 2020;21(1):784. doi: 10.1186/s13063-020-04711-6.
    1. Silverberg SL, Puchalski Ritchie LM, Gobat N, Nichol A, Murthy S. Clinician-researcher’s perspectives on clinical research during the COVID19 pandemic. PLoS One. 2020;15(12):e0243525. doi: 10.1371/journal.pone.0243525.
    1. Kozlowski HN, Farkouh ME, Irwin MS, Radvanyi LG, Schimmer AD, Tabori U, et al. COVID-19: a pandemic experience that illuminates potential reforms to health research. EMBO Mol Med. 2020;12(11):e13278. doi: 10.15252/emmm.202013278.
    1. Almufleh A, Joseph J. The time is now: role of pragmatic clinical trials in guiding response to global pandemics. Trials. 2021;22(1):229. doi: 10.1186/s13063-021-05165-0.
    1. Tuttle KR. Impact of the COVID-19 pandemic on clinical research. Nat Rev Nephrol. 2020;16(10):562–564. doi: 10.1038/s41581-020-00336-9.
    1. Bierer BE, White SA, Barnes JM, Gelinas L. Ethical challenges in clinical research during the COVID-19 pandemic. J Bioeth Inq. 2020;17(4):717–722. doi: 10.1007/s11673-020-10045-4.
    1. McDermott MM, Newman AB. Preserving clinical trial integrity during the coronavirus pandemic. JAMA. 2020;323(21):2135–2136. doi: 10.1001/jama.2020.4689.
    1. Collier EK, Hsiao JL, Shi VY. Conducting clinical trials during the COVID-19 pandemic. J Dermatolog Treat. 2020;31(4):330–332. doi: 10.1080/09546634.2020.1759770.
    1. Becker G, Martin T, Sabo AN, Bertrand F, Hutt A, Ayme-Dietrich E, Michel B, Monassier L, Gourieux B. Impact of the COVID-19 pandemic on clinical research in hospitals: observational study in the first epicenter of the epidemic during the general lockdown in France. Eur Rev Med Pharmacol Sci. 2021;25:1158–1162. doi: 10.26355/eurrev_202101_24686.
    1. Gelfand JM, Hefele BE. Clinical research after COVID-19: embracing a new normal. J Invest Dermatol. 2021;141(3):481–483. doi: 10.1016/j.jid.2020.08.004.
    1. Emamaullee J, Bowdish M, Yan PY, Rodina V, Sher LS. Rapid adaptation of a surgical research unit to conduct clinical trials during the COVID-19 pandemic. J Surg Res. 2020;256:76–82. doi: 10.1016/j.jss.2020.06.049.
    1. Freer PE. The impact of the COVID-19 pandemic on breast imaging. Radiol Clin North Am. 2021;59(1):1–11. doi: 10.1016/j.rcl.2020.09.008.
    1. Campanella S, Arikan K, Babiloni C, Balconi M, Bertollo M, Betti V, Bianchi L, Brunovsky M, Buttinelli C, Comani S, di Lorenzo G, Dumalin D, Escera C, Fallgatter A, Fisher D, Giordano GM, Guntekin B, Imperatori C, Ishii R, Kajosch H, Kiang M, López-Caneda E, Missonnier P, Mucci A, Olbrich S, Otte G, Perrottelli A, Pizzuti A, Pinal D, Salisbury D, Tang Y, Tisei P, Wang J, Winkler I, Yuan J, Pogarell O. Special report on the impact of the COVID-19 pandemic on clinical EEG and research and consensus recommendations for the safe use of EEG. Clin EEG Neurosci. 2021;52(1):3–28. doi: 10.1177/1550059420954054.
    1. Taylor-Cousar JL, Maier L, Downey GP, Wechsler ME. Restarting respiratory clinical research in the era of the coronavirus disease 2019 pandemic. Chest. 2021;159(3):1173–1181. doi: 10.1016/j.chest.2020.11.001.
    1. Trethewey SP, Beck KJ, Symonds RF. Video consultations in UK primary care in response to the COVID-19 pandemic. Br J Gen Pract. 2020;70(694):228–229. doi: 10.3399/bjgp20X709505.
    1. Bensoussan E, Ouldali N, Ashkenazi S, Angoulvant F, Cohen R, Levy C. Impact of coronavirus disease 2019 (COVID-19) pandemic on pediatric infectious disease research. J Pediatr. 2021;230:279–281.e2. doi: 10.1016/j.jpeds.2020.11.052.
    1. Fleming TR, Labriola D, Wittes J. Conducting clinical research during the COVID-19 pandemic: protecting scientific integrity. JAMA. 2020;324(1):33–34. doi: 10.1001/jama.2020.9286.
    1. Gao F, Tao L, Huang Y, Shu Z. Management and data sharing of COVID-19 pandemic information. Biopreserv Biobank. 2020;18(6):570–580. doi: 10.1089/bio.2020.0134.
    1. Mahalmani VM, Semwal A, Kaur H, Kaur S, Prakash A, Medhi B. Pattern of clinical research in the era of COVID-19 pandemic: a new learning experience for the present as well as future. Indian J Pharmacol. 2020;52(4):249–253. doi: 10.4103/ijp.IJP_669_20.
    1. Largent EA, Halpern SD, Fernandez LH. Waivers and alterations of research informed consent during the COVID-19 pandemic. Ann Intern Med. 2021;174(3):415–416. doi: 10.7326/M20-6993.
    1. Straiton N, McKenzie A, Bowden J, Nichol A, Murphy R, Snelling T, Zalcberg J, Clements J, Stubbs J, Economides A, Kent D, Ansell J, Symons T. Facing the ethical challenges: consumer involvement in COVID-19 pandemic research. J Bioeth Inq. 2020;17(4):743–748. doi: 10.1007/s11673-020-10060-5.
    1. Witham MD, Anderson E, Carroll CB, et al. Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project. BMJ Open. 2020;10(11):e043634. doi: 10.1136/bmjopen-2020-043634.
    1. Sohrabi C, Mathew G, Franchi T, Kerwan A, Griffin M, Soleil C del Mundo J, Ali SA, Agha M, Agha R. Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training - a review. Int J Surg. 2021;86:57–63. doi: 10.1016/j.ijsu.2020.12.008.
    1. Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, Chen Y, Han Y. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020;106:1132–1141. doi: 10.1136/heartjnl-2020.317056.
    1. Hsia B, Greige N, Quiroz J, Khokhar A, Daily J, Biase L, Ferrick K, Fisher J, Krumerman A. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. J Intervent Card Electrophysiol. 2020;59(2):337–345. doi: 10.1007/s10840-020-00822-x.
    1. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19) Mayo Clin Proc. 2020;95(6):1213–1221. doi: 10.1016/j.mayocp.2020.03.024.
    1. FDA guidance on conduct of clinical trials of medical products during the COVID-19 public health emergency Guidance for Industry, Investigators, and Institutional Review Boards. MARCH 2020
    1. Gao H, Duan X, Guo X, Huang A, Jiao B. Design and tests of a smartphones-based multi-lead ECG monitoring system. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:2267–2270. doi: 10.1109/EMBC.2013.6609989.
    1. National Institute for Health and Care Excellence. KardiaMobile for the ambulatory detection of atrial fibrillation. Medtech innovation briefing [MIB232] published 29 October 2020. Accessed 25 Nov 2020 at .
    1. Barnabas RV, Brown E, Bershteyn A, Miller RS, Wener M, Celum C, Wald A, Chu H, Wesche D, Baeten JM, for the Hydroxychloroquine COVID-19 PEP Study Team Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):475. doi: 10.1186/s13063-020-04446-4.
    1. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. NEJM. 2020;383(6):517–525. doi: 10.1056/NEJMoa2016638.
    1. Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. BCN-PEP-CoV2 Research Group. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. 2021;384(5):417–427. doi: 10.1056/NEJMoa2021801.
    1. Avidan MS, Dehbi H-M, Delany-Moretlwe S. Hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(11):1087–8. 10.1056/NEJMc2023617.
    1. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang ML, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM, Hydroxychloroquine COVID-19 PEP Study Team Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial [published correction appears in Ann Intern Med. 2021 Mar;174(3):435] Ann Intern Med. 2021;174(3):344–352. doi: 10.7326/M20-6519.
    1. United States Food and Drug Administration: News release “Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine,” June 15, 2020.
    1. Lewis K, Chaudhuri D, Alshamsi F, Carayannopoulos L, Dearness K, Chagla Z, et al. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: a systematic review and meta-analysis of randomized trials. PLoS One. 2021;16(1):e0244778. doi: 10.1371/journal.pone.0244778.
    1. RECOVERY: Randomised evaluation of COVID-19 therapy. . accessed 1 Aug 2021.
    1. Walker J. COVID treatment options remain elusive, despite months of effort and rising delta cases. . accessed 21 July 2021.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa